Core Technology and Innovation

The company?s operations were built on the integration of two proprietary technology platforms:

• Gene Activated Matrix (GAM): Originally developed by Matrigen, this technology involved the use of a structural matrix (often collagen-based) impregnated with DNA encoding for specific therapeutic proteins. When applied to a wound or surgical site, the matrix served as a scaffold that "trained" the patient's own cells to produce the necessary healing proteins locally.
• Fibroblast Growth Factor (FGF) Targeting: Developed by Prizm Pharmaceuticals, this technology utilized growth factor ligands to deliver genetic material specifically to cells involved in the repair and regeneration of tissue.

Products and Therapeutic Pipeline

Selective Genetics focused on creating "bio-active" surgical implants and topical treatments. Their product pipeline was primarily directed toward orthopedic and wound care applications:

1. Orthopedic Repair (Selective Bone Regeneration)

The company developed products designed to accelerate the healing of complex bone fractures and spinal fusions. * GAM-Based Implants: These were biodegradable scaffolds containing DNA for bone morphogenetic proteins (BMPs). Unlike traditional protein-based treatments which can wash away, the GAM approach allowed for the sustained, local production of BMPs by the patient's own cells at the site of the injury. * Application: Used in "non-union" fractures where the bone fails to heal on its own and in spinal fusion surgeries to promote faster bone growth between vertebrae.

2. Chronic Wound Healing

Selective Genetics applied its site-specific delivery technology to treat non-healing wounds, particularly those associated with diabetes. * Topical Gene Therapeutics: These products delivered genes for growth factors (such as PDGF or FGF) directly to the wound bed. * Objective: To stimulate angiogenesis (the formation of new blood vessels) and the migration of fibroblasts to close the wound and prevent infection or amputation.

3. Cardiovascular and Vascular Repair

The company explored the use of gene-targeted ligands to treat vascular conditions. * Vascular Stent Coatings: Research into coating medical devices with gene-activated matrices to prevent restenosis (the re-narrowing of an artery) by delivering genes that regulate smooth muscle cell growth.

Services and Research Operations

Beyond its direct product pipeline, Selective Genetics functioned as a high-level research and development entity, offering:

• Collaborative Research Agreements: Partnering with larger pharmaceutical and medical device companies to integrate gene-activated technologies into existing surgical products.
• Site-Specific Delivery Consulting: Providing expertise in the targeting of viral and non-viral vectors to specific tissue types, such as bone, skin, and vascular endothelium.
• Biocompatibility Testing: Extensive laboratory services to ensure that their synthetic and biological matrices interacted safely with human tissue without triggering adverse immune responses.

Strategic Position and Industry Legacy

During its active years, Selective Genetics was considered a "next-generation" gene therapy company because it moved away from systemic (whole-body) gene delivery in favor of localized, surgical applications. This approach was designed to minimize side effects and increase the efficacy of the treatment.

The company was backed by premier venture capital firms, including Domain Associates and New Leaf Venture Partners. While Selective Genetics eventually ceased independent operations, its foundational research into Gene Activated Matrices (GAMs) continues to influence modern regenerative medicine, particularly in the fields of tissue engineering and 3D-printed bio-scaffolds.